Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 10, 2026

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

Targeting CD38 in Antibody-Mediated Rejection.

Katharina A Mayer1, Klemens Budde2, Matthias Diebold1,3

  • 1Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria.

Transplant International : Official Journal of the European Society for Organ Transplantation
|May 30, 2025
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Donor bone marrow together with recipient regulatory T cells induces chimerism without irradiation in kidney transplantation.

Science translational medicine·2026
Same author

Clazakizumab in the treatment of chronic active antibody-mediated kidney transplant rejection: Results from the IMAGINE phase 3, randomized, double-blind, placebo-controlled study.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

The Banff 2024 Kidney Meeting Report: Rejection as a spectrum of phenotypes and focus on differential diagnostic reasoning.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

DARC and Anti-Duffy Antibodies in the Line of Fire: The Challenges in Pinpointing the Etiology of Microcirculation Inflammation to a Distinct Entity.

Transplant international : official journal of the European Society for Organ Transplantation·2026
Same author

Crovalimab Rescue Therapy in a Case With Genetic Complement Mediated Thrombotic Microangiopathy.

Kidney medicine·2026
Same author

International Kidney Paired Donation Programs: Evolution and Practices of 4 Large Collaborations.

Transplantation·2025
Same journal

Cold ischemia time exceeding 12 hours is a risk factor for delayed graft function and increased mortality in kidney transplant recipients within the eurotransplant senior program.

Transplant international : official journal of the European Society for Organ Transplantation·2026
Same journal

Impact of pre-transplantation exposure to immunosuppressive agents on lung transplant outcomes in interstitial lung disease.

Transplant international : official journal of the European Society for Organ Transplantation·2026
Same journal

Delayed graft function and long-term outcomes after deceased donor kidney transplantation: insights from mate-kidney analysis.

Transplant international : official journal of the European Society for Organ Transplantation·2026
Same journal

Regulatory approach to manipulated organs in Europe: preserving human organs as non-commercial goods.

Transplant international : official journal of the European Society for Organ Transplantation·2026
Same journal

Can european law keep pace with biomedical innovation? The reinvention of transplantation regulation.

Transplant international : official journal of the European Society for Organ Transplantation·2026
Same journal

Sex-related differences in survival based on [<sup>18</sup>F]FDG PET/CT metabolic tumor volume after liver transplantation for colorectal liver metastases.

Transplant international : official journal of the European Society for Organ Transplantation·2026
See all related articles

CD38-targeted therapy, like felzartamab, shows promise in treating late antibody-mediated rejection (AMR) after transplantation by reducing inflammation and NK cells. While effective, its impact on donor-specific antibodies is limited, with ongoing trials exploring prolonged treatment benefits.

Area of Science:

  • Immunology
  • Transplantation Medicine
  • Oncology

Background:

  • Antibody-mediated rejection (AMR) is a significant obstacle in organ transplantation, with current treatments offering variable success rates.
  • CD38, a target on plasma cells and NK cells, presents a potential therapeutic avenue for AMR by addressing both antibody production and cellular rejection mechanisms.

Purpose of the Study:

  • To review recent advancements in CD38-targeted therapies for AMR, focusing on felzartamab's efficacy and safety.
  • To explore the dual mechanism of CD38 targeting in mitigating AMR pathophysiology.

Main Methods:

  • Review of clinical data, including phase 2 trial results for felzartamab in late AMR.
  • Analysis of felzartamab's effects on microvascular inflammation, gene expression, cell-free DNA, NK cell counts, and donor-specific antibodies.
Keywords:
CD38antibody-mediated rejectionkidney transplantationnatural killer cellstreatment

Related Experiment Videos

Last Updated: May 10, 2026

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

Main Results:

  • Felzartamab demonstrated safety and efficacy in a phase 2 trial for late AMR, leading to reduced microvascular inflammation and rejection markers.
  • Treatment correlated with decreased NK cell counts and donor-derived cell-free DNA, but did not significantly impact donor-specific antibodies.
  • Observed effects on rejection activity were rapid but transient, prompting further investigation into prolonged therapy.

Conclusions:

  • CD38-targeted therapy, exemplified by felzartamab, offers a promising strategy for managing late AMR, primarily through NK cell depletion.
  • Further research, including phase 3 trials, is warranted to establish the long-term benefits and expand applications to early AMR or other transplant complications.